MMV688533   Click here for help

GtoPdb Ligand ID: 11704

Synonyms: MMV533 | SAR121 | SAR441121
Antimalarial Ligand
Compound class: Synthetic organic
Comment: MMV688533 is the optimized lead from the acylguanidine series of antimalarial compounds [1]. The compound has progressed to clinical evaluation and was awarded MMV Project of the Year (2017).

The Malaria tab on this ligand page provides additional curator comments of relevance to the Guide to MALARIA PHARMACOLOGY.
2D Structure
Click here for help
Click here for structure editor
Physico-chemical Properties
Click here for help
Hydrogen bond acceptors 7
Hydrogen bond donors 4
Rotatable bonds 8
Topological polar surface area 120.96
Molecular weight 519.11
XLogP 6.04
No. Lipinski's rules broken 1
SMILES / InChI / InChIKey
Click here for help
Canonical SMILES NC(=N)NC(=O)c1cc(C#Cc2ccc(c(c2)C(=O)Nc2ccccn2)C(F)(F)F)cc(c1)C(F)(F)F
Isomeric SMILES NC(=N)NC(=O)c1cc(C#Cc2ccc(c(c2)C(=O)Nc2ccccn2)C(F)(F)F)cc(c1)C(F)(F)F
InChI InChI=1S/C24H15F6N5O2/c25-23(26,27)16-10-14(9-15(12-16)20(36)35-22(31)32)5-4-13-6-7-18(24(28,29)30)17(11-13)21(37)34-19-3-1-2-8-33-19/h1-3,6-12H,(H,33,34,37)(H4,31,32,35,36)
InChI Key GGTONGQHYUQSBR-UHFFFAOYSA-N
No information available.
Summary of Clinical Use Click here for help
MMV688533 has entered Phase 1 clinical assessment for malaria (NCT04323306).
Clinical Trials
Clinical Trial ID Title Type Source Comment References
NCT04323306 A Phase 1 Study to Assess the Safety, Tolerability, and Pharmacokinetic Profile of a Single Doses of MMV533. Phase 1 Interventional Medicines for Malaria Venture